Euprotec, Cantab Enter Antibiotics Development Pact

Euprotec, Ltd. has entered an alliance with Cantab Anti-infectives to develop improved antibiotics to treat multidrug resistant Gram-negative bacterial infections.The program will focus on developing improved therapeutics based on polymyxin, a class of antibiotics with a unique and important target and are currently viewed as a last resort when treating severe infections due to multidrug resistant Gram negative bacteria.
 
Euprotec will provide microbiology services to help facilitate the identification and optimization of a new drug candidate using its biology platform and highly characterized collection of bacteria to optimize the potency and efficacy of new compounds. The approach will allow profiling of PKPD parameters for translation of preclinical data to clinical trials.
 
Dr. Lloyd Payne, chief executive of Euprotec, said, “We are thrilled that Cantab has selected Euprotec as its infectious disease biology partner for this programme.  Multidrug resistant Gram negative bacterial infections pose an enormous threat, and we look forward to working with Cantab to realise the exciting potential of their antibiotic platform.”
 
Dr. Mike Dawson, chief executive of Cantab, said, “We selected Euprotec as our primary biology partner for this programme due to its strong reputation for delivery in the infectious disease therapeutic area as well as the depth and breadth of their portfolio and expertise. The specialist knowledge and technical skills that Euprotec provides will supplement our in-house research team perfectly and we are looking forward to working with them as we progress our discovery and development program.”